Bimekizumab maintenance of response and safety in patients with moderate to severe plaque psoriasis: Results from the open-label extension period (Weeks 48–144) of the **BE RADIANT phase 3b trial**

Objectives

To evaluate the efficacy of bimekizumab (BKZ), as measured by complete or near complete skin clearance using the Psoriasis Area and Severity Index (PASI), and long-term safety of BKZ in patients with moderate to severe plaque psoriasis over Weeks 48-144 of the BE RADIANT phase 3b trial.

Background

- Patients who completed the 48-week double-blind period in the BE RADIANT (NCT03536884) phase 3b trial could enter the open-label extension (OLE).¹
- Clinical improvements in BKZ-treated patients, including patients who switched to BKZ from secukinumab (SEC), have been reported previously through Week 96 of BE RADIANT, with no unexpected safety findings.¹⁻³

Methods

- This analysis included patients who were randomized to BKZ or SEC at baseline and who were enrolled in the OLE (Weeks 48-144) of the BE RADIANT phase 3b trial
- All patients received BKZ 320 mg every 4 weeks (Q4W) or 8 weeks (Q8W) in the OLE; all switched to Q8W from Week 64 onwards (Figure 1).

Efficacy

- PASI response rates were evaluated for patients who were treated with BKZ or SEC until Week 48 and entered the OLE.
- Efficacy data are reported using observed case (OC), modified non-responder imputation (mNRI), and non-responder imputation (NRI).
- For mNRI, patients discontinuing due to lack of efficacy or treatment-related adverse events (AEs) were considered non-responders; multiple imputation was used for other missing data.

Safety

- Safety data, evaluated as incidence of new cases per 100 patient-years (PY), were grouped for all patients who received ≥ 1 BKZ dose in the OLE.
- Data were pooled for all patients who received >1 BKZ dose at Week 48 or later (BKZ Total), up to the data cut-off of May 31, 2022, the date on which the last enrolled patient reached Week 144.
- Treatment-emergent adverse events (TEAEs) were coded according to MedDRA v19.0.

Results


- Baseline characteristics have been reported previously and were similar between the groups examined.²
- PASI responses were maintained or improved throughout the OLE period to Week 144; 89.8% of patients in the Continuous BKZ group, and 87.0% of patients who switched to BKZ from SEC, achieved PASI <2 at Week 144. Similarly, 68.8% of patients in the Continuous BKZ group, and 69.1% of patients in the SEC/BKZ group, achieved PASI 100 at Week 144 (Figure 2).
- Incidence rates of serious TEAEs and discontinuations were low (Table 1)
- Four deaths occurred; two from coronavirus infection in high-risk (obesity and diabetes mellitus) unvaccinated patients. None of the deaths were assessed as treatment-related
- The most frequent fungal infection was oral candidiasis. Most oral candidiasis cases were mild or moderate (98.3%); none were serious, and three led to discontinuation

Conclusions

Clinical improvements achieved after one year of BKZ treatment were maintained for up to two further years, throughout the OLE (Weeks 48-144), among patients who entered this period.

Outcomes improved and were durable to Week 144 in SEC-treated patients who switched to BKZ upon entering the OLE.

Adverse events reported over the second and third year of treatment were consistent with the safety profile of BKZ-treated groups reported previously over one and two years of treatment.^{1,2,4}



Presented at Maui Derm NP+PA Summer 2023 | June 21–24 | Colorado Springs, CO